Recombinant single-chain urokinase-type plasminogen activator (rscu-pa) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis by Sohnge, Wolfgang et al.
THROMBOSIS RESEARCH 51; 63-74, 1988 
0049-3848188 $3.00 + .OO. Printed in the USA. 
Copyright (c) 1988 Pergamon Press plc. All rights reserved. 
RECOMBINANT SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN 
ACTIVATOR (rscu-PA) INDUCES THROMBOLYSIS AND SYSTEMIC 
FIBRINOLYSIS IN A CANINE MODEL OF CORONARY ARTERY THROMBOSIS 
Wolfgang Sohngen, Judith K. Mickelson, Paul J. Simpson and Benedict R. Lucchesi 
Department of Pharmacology 
The University of Michigan Medical School 
Ann Arbor, Michigan, USA 
(Received 12.10.1987; Accepted in revised form 22.4.1988 
by Editor N.U. Bang) 
Abstract: The thrombolytic efficacy of recombinant single-chain urokinase-type plasminogen 
activator (rscu-PA) was studied in an open-chest canine model of coronary artery 
thrombosis. Dogs (n=16) were anesthetized, a left thoracotomy performed, and a 
two cm segment of the left circumflex coronary artery was isolated and instrumented 
with an electromagnetic flow probe, an intracoronary stimulation electrode, and an 
adjustable mechanical occluder. Anodal direct current (100 PA) was applied to the 
stimulation electrode until thrombosis occurred ‘(n=14). After 30 min of thrombotic 
occlusion, rscu-PA was administered intravenously. Dogs were sacrificed either 6 h 
after thrombolysis or 6.5 h after initiation of rscu-PA when thrombolysis did not 
occur. In group A (30-50 l.tg/kg bolus rscu-PA + 20-40 p.g/kg/min infusion rscu-PA 
for 30 min, n=5) thrombolysis occurred in one case (20%) and this artery 
reoccluded. In group B (250 pg/kg bolus rscu-PA + 25 pg/kgtin infusion rscu-PA 
for 30 min, n=6) all reperfused and only one reoccluded (16.6%). In group C (200 
pg/kg bolus rscu-PA + 100 pg/kg/min rscu-PA infusion for 30 min, n=2) both 
reperfused and neither reoccluded. Infarct size, determined as a percentage of left 
ventricle, was smaller when thrombolysis was followed by persistent reperfusion 
(n=7), than when reperfusion did not occur (n=4): 16.9 + 3.7% vs 31.3 + 2.2%, 
respectively (mean fSEM, ~~0.02). If thrombolysis was followed by reocclusion, 
infarct size was 27.0 f 10.0%. In this study thrombolysis occurred when changes in 
prothrombin time, partial thromboplastin time, fibrinogen and fibrin split products 
were suggestive of systemic finbrinogenolysis. In conclusion, effective 
thrombolysis with rscu-PA appears to limit infarct size and to be accompanied by 
evidence of systemic fibrinolysis. 
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oduction 
Thrombolytic therapy in the early stage of evolving myocardial infarction has been shown to be 
beneficial clinically (l-4). However, defining the optimal dose regimen which would provide 
rapid thrombolysis and prevent reocclusion without significant bleeding complications has been 
difficult (5). The clot specific fibrinolytic agents, tissue-type plasminogen activator (t-PA) and 
recombinant single-chain urokinase-type plasminogen activator (rscu-PA), were expected to be 
more effective and safer thrombolytic agents. 
The mechanism of action for clot-specific thrombolysis is different for t-PA and rscu-PA. Specific 
plasma inhibitors of t-PA may limit its action in the absence of fibrin (6). The clot specificity of 
t-PA is due to its affinity for plasminogen in the presence of fibrin (7). The fibrin selective clot 
lysis of scu-PA is due to activation of plasminogen bound to fibrin in the lys-plasminogen-like 
conformation, while the usual circulating glu-plasminogen form is spared (8). Plasma inhibitors of 
scu-PA have not been demonstrated. However, different forms of single-chain urokinase are to be 
expected to have different half-lives and enzyme activities (9). 
In experimental studies, scu-PA and rscu-PA were found to be effective thrombolytic agents which 
did not induce systemic fibrinolysis unless a dose wasused which exceeded the relative threshold 
of specificity (10-16). Species variability in fibrinolytic responses to rscu-PA has been reported 
(15), as has fibrinogenolysis with high doses of rscu-PA (15,16). When used in a canine model of 
coronary artery thrombosis, both t-PA and rscu-PA were effective without inducing systemic 
fibrinolysis when the thrombus was generated with a copper coil (11,12,17). However in humans 
and in the canine model of coronary artery thrombosis that was used in this study, rscu-PA and 
rt-PA caused systemic fibrinolysis when administered in a sufficient dose to achieve effective 
thrombolysis (18-21). Whether or not these laboratory findings predict clinically significant 
bleeding complications has yet to be established. 
We investigated rscu-PA in a well-defined canine model of coronary artery thrombosis (22) to 
determine its (a) thrombolytic efficacy, (b) ability to maintain vessel patency after initial 
thrombolysis, (d) systemic fibrinolytic effects, and (e) influence on infarct size after 
thrombosis/thrombolysis and reperfusion myocardial injury. 
Surgical Sixteen male mongrel dogs (14-2 1 kg) were anesthetized with pentobarbital 
sodium (30 mg/kg i.v.), intubated and ventilated with room air at a tidal volume of 30 ml/kg and a 
frequency of 12 breaths/min (Harvard respirator). The left carotid artery and internal jugular vein 
were exposed and catheters were inserted for monitoring arterial pressure (Statham P23DC 
pressure transducer) and infusion of drugs, respectively. A left thoracotomy was performed in the 
fifth intercostal space and the heart was suspended in a pericardial cradle. A two cm section of 
the left circumflex coronary artery was isolated proximal to the first marginal branch and 
instrumented proximal to distal as follows: electromagnetic flow probe (Carolina Medical 
Electronics Model 501), stimulation electrode and a teflon screw-occluder. The stimulation 
electrode consisted of a 25-gauge hypodermic needle tip attached to a 30-gauge Teflon-insulated 
silver-coated copper wire (Figure 1). The occluder was adjusted to decrease the reactive hyperemic 
flow by 50-70% without affecting mean resting coronary blood flow (23) (Figure 2). The small 
intervening coronary branches over the l-2 cm segment were ligated. Continuous recordings of 
blood pressure, the standard lead II electrocardiogram, mean and phasic left circumflex coronary 
artery blood flow were recorded on a Grass Model 7 polygraph. Zero flow and hyperemic flows 
were determined by occluding the circumflex coronary artery distal to the flow probe for 10 sec. 
The flow probe was calibrated using heparinized whole blood. Dogs were allowed to stabilize after 
the surgical procedure for 30 min before the electrical stimulation was started. If thrombosis 
occurred, 30 mg of lidocaine hydrochloride was given intravenously. Six hours after thrombolysis 
or 6.5 h after thrombotic occlusion (if no thrombolysis occurred), the dogs were euthanized and 
the hearts removed quickly for postmortem quantification of infarct size and determination of 
thrombus mass (mg). 
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In order to determine the thrombus mass, it was 
necessary to dissect and remove a portion of the coronary artery. Therefore quantification of the 
area at risk for infarction with the dual staining technique was not possible (24). Rather, the heart 
was cut into six equal sections, 1.0-1.5 cm thick, perpendicular to the apex-base axis and 
immersed in 1.5% triphenyltetrazolium hydrochloride in 20 mM potassium phosphate buffer (pH 
7.4,38”C) for 5 min. The presence of dehydrogenase enzymes in viable myocardial regions leads 
to reduction of tetrazolium salt and the development of a red formazan precipitate in the heart 
tissue. Infarcted tissue did not reduce tetrazolium salt and remained pale tan in color (2526). The 
sections were trimmed of right ventricular, valvular, and fatty tissue and weighed. Infarct size was 
determined using computer-assisted planimetry. Infarct size was expressed as percentage of the 
total left ventricle. 
lation Stlbdles; The prothrombin time (PT) was determined with thromboplastin C [dried 
rabbit brain thromboplastin with calcium (Becton, Dickinson and Co., Rutherford, NJ 07070)] 
The maximum time measured was 60 sec. Activated partial thromboplastin time (PIT) was 
determined using calcium chloride (0.02 M) and activated cephaloplastin reagent [liquid rabbit 
brain cephalin with plasma activator (Becton, Dickinson and Co., Rutherford, NJ 07070)]. The 
maximum time measured was 150 sec. Fibrinogen levels were determined with thrombin reagent 
[lyophilized bovine thrombin, 100 NM units/ml (Becton,Dickinson and CO., Rutherford, NJ 
07070)] and Owren’s Verona1 buffer M sodium barbital in 0.125 M NaCl, pH 7.35). The 
minimum amount measurable was 15 mg/dl. Control plasma for the PT, P’IT, and fibrinogen 
assays was a lyophilized preparation of human plasma [Ci-Trol Coagulation Control, Level I 
(American Dade, Aguada, Puerto Rico 00602)]. Fibrin(ogen) split products (FSP) or degradation 
products (FDP) were measured with immunological methods observing the agglutination of Latex 
Anti-Fibrinogen [0.6% suspension of polystyrene latex particles coated with rabbit anti-human 
fibrinogen in buffer (American Dade, Aguada, Puerto Rico 00602)] and Sorensen’s glycine buffer 
(0.1 M glycine and 0.1 M saline, pH 8.2). Sample tubes for FSP assays contained thrombin (20 
NlH units) and soy bean trypsin inhibitor [approx. 3600 NF units (Wellcome Laboratories, 
Beckenham,U.K.)]. Vaccutainer tubes for PT, PTT and fibrinogen contained 0.5 ml of 3.2% 
buffered sodium citrate (Becton Dickinson, Rutherford, N.J.). Platelet counts were determined 
using a J.T. Baker MK/4Hc platelet counting system. 
Drugs; Recombinant single-chain urokinase-type plasminogen activator, a gift from Grtinenthal 
GmbH (Aachen, West Germany, Drs. Flohe and Giinzler), was produced from E. coli sources 
(Mr 47,000) and contained 0.09% double chain urokinase activity. Lidocaine hydrochloride was 
purchased from Sigma (StLouis, MO.). 
cal Anal- The data are expressed as the mean + SEM (standard error of the mean). The 
groups were compared using one way analysis of variance and Student’s t-test. A p value less than 
0.05 was considered significant. Changes within groups were established by repeated measures of 
ANOVA and significance between means was determined using Scheffe’s test. 
Exnerimental Pro&& After surgical preparation, the dogs were allowed to stabilize and then the 
electrical stimulation was initiated. If comolete occlusive thrombus was not established within 4 h 
the dogs were excluded from the study. if coronary artery thrombosis occurred, as assessed by 
zero coronary blood flow and ST segment-elevation in the lead II electrocardiogram, then electrical 
stimulation was discontinued 30 min after thrombotic occlusion and thrombolytic treatment was 
initiated. Blood samples for coagulation studies were taken initially and at 5 and 30 min after the 
bolus was given and 1, 3 and 6 h after the initiation of the treatment. Three rscu-PA treatment 
groups (varying dose schedules) were studied: 
Group A: 30-50 pg/kg bolus + 20-40 pg/kg/rnin infusion over 30 min 
(total dose = 0.64- 1.25 mg/kg, n=5) 
Group B: 250 pg/kg bolus + 25 pg/kg/min infusion over 30 min 
(total dose =l mg/kg, n=6) 
Group C: 200 p.g/lcg bolus + 100 pg/kg/min infusion over 30 min 
(total dose = 3.2 mg/kg, n=2) 
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hyperemic response is reduced approximately by 50% whereas the mean basal flow is unaffected. 
A total of 16 dogs were used in the study. Two dogs were excluded because they did not develop 
coronary artery thrombosis after 4 h of electrical stimulation. Since postmortem examination of the 
vessel revealed that the wire had been in place, it was concluded that the lack of thrombus 
formation was due to initial low platelet counts (<50,000/mm3). One dog was excluded because 
the infusion was accidently started 30 min after the bolus. Interestingly, reperfusion was achieved 
in this case. Since group C is small (n=2), the results of this group will be presented separately. 
The following paragraphs compare the results of groups A and B. 
Thrombosis.sis. reocclusion. and thrombus weight; There was no significant difference 
between groups A and B with respect to the time required to develop a fully occlusive thrombus 
(75.2 + 24.3 min vs 98.8 + 26.5 min, respectively). In group A, thrombolysis occurred in115 
(20%) and this was followed by reocclusion. In group B, thrombolysis occurred in all 6, and only 
l/6 (16.6%) reoccluded. The time necessary to achieve thrombolysis for the one case in group A 
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was 25 min and for all 6 cases in group B was 16.3 f 4.3 min. The difference in thrombus weight 
between the two groups nearly reached significance (30.2 f 7.0 mg group A vs 10.9 + 5.7 mg 
group B, p=O.O6). In group A, reocclusion occurred 95 min after thrombolysis (n=l); whereas 
only 116 vessels reoccluded in group B and this occurred after 20 min. Reocclusion developed 
gradually and was not accompanied by oscillations in coronary blood flow as has been described 
by Schumacher et al (26). 
ble In the beginning of the experiments there was a tendency 
towards higher mean arterial pressure (MAP) and heart rate (HR) in group B compared to group A. 
These differences however became less prominent over the course of the experiment and final 
values were not different. Left circumflex coronary blood flow (CBF) was similar before 
thrombosis (20.5f2.2 ml/min group A vs 27.3ti.5 ml/min group B). Neither the administration 
of a low dose or high dose bolus, nor the 30 min infusion had an effect on MAP, HR or CBF. In 
group A thrombolysis occurred in one dog, whereas in group B thrombolysis occurred in all 
[initial reperfusion CBF: 18 ml/mm (n=l) vsl1.7k3.7 ml/mm (n=6), respectively]. In the patent 
vessels of group B, CBF was 15.4k3.6 ml/mm (n=5) after 6 h of reperfusion, a trend toward 
increasing CBF over time. By this point in time, the one patent vessel had reoccluded in Group A. 
on studies; In preliminary experiments it was established that the soy bean trypsin 
inhibitor successfully inhibits activation of plasminogen to plasmin while the sample was being 
processed. This was essential to ensure that the measured fibrinlogen split or degradation products 
(FSP or FDP) were not an artifact that occurred in the test tube due to ongoing activation by a 
tissue-type plasminogen activator (27). When samples were taken 5 min after bolus injection there 
was no detectable difference in prothrombin time (PT), partial thromboplastin time (PTT), FSP or 
fibrinogen measured initially or after several hours, thus indicating that plasminogen activation in 
the test tube was negligible and that the soy bean inhibitor was effective in preventing proteolysis 
of fibrinogen by plasmin. Compared to normal human plasma, the values in dogs for PT and P’IT 
were 50% shorter, fibrinogen was similar, and FSP were minimally elevated after thoracotomy. 
The values for PT, PIT, fibrinogen and FSP were similar between the two groups before 
treatment (baseline values were taken after thoracotomy). Platelet counts were similar for the two 
groups (data not shown). 
The PT for group B (42.3 + 11.2 ) was prolonged at 30 min after the onset of treatment compared 
to group A (~0.02) and there was a significant change over time within group B. Over time there 
were no changes detected in the PT for group A. The P’IT in group B (104.1 f 29.0) was 
prolonged at 30 min and this was a significant increase compared to baseline. Fibrinogen was 
lower in group B than group A 3 h and 6 h after starting therapy (~~0.05 and ~~0.02, 
respectively). Within both groups there were significant decreases in fibrinogen over time: in 
group A at 30 min, 1 h and 3 h and in group B from 30 min throughout 6 h. The FSP were 
increased in group B compared to group A at 6 h @<O.OS). Within the groups significant increases 
for FSP were present over the course of the experiments: in group A at 3 h and in group B at 1 h. 
It seems that abnormalities in the coagulation pathway were necessary for thrombolysis to occur. 
There was a tendency to normalization of the abnormal coagulation parameters towards the end of 
the experiments. The lack of differences within and between groups and the large SEM with 
respect to coagulation parameters was an indicator of the variability of the dog’s response to 
fibrinolytic agents. Statistical analysis of the data for PT and PlT may have been influenced by 
arbitrary upper limits of sensitivity of the assays (60 set and 150 set, respectively). It is important 
to note that none of the dogs exhibited substantial bleeding, even though an open-chest model was 
used. A summary of the findings in regard to coagulation parameters is given in figure 3. 
Infarct Although measurements of infarct sizes, especially when the area at risk is not defined 
and when collateral blood flow is not measured, have to be noted with caution, postmortem infarct 
sizes can still be regarded as a reasonable estimate of myocardial tissue injury. Infarct size, 
expressed as percentage of the left ventricle, was smaller in groups B than group A (19.0+_3.4% vs 
34.4k3.68, respectively, ~~0.02). This finding suggested that thrombolysis occurring early in 
evolving myocardial infarction reduced infarct size. Whether or not there were additional 
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Figure 3; Coagulation profile over the time of the experiment. l=Baseline, 2=5 min after bolus, 
3=30 min after bolus, 4=1 h after bolus, 5=3 h after bolus, 6=final. *=p<O.O5, **=p<O.O2, 
a=differences within Group A compared to baseline, b=differences within group B compared to 
baseline (a+b ~~0.05 with Scheffe’s test). 
mechanisms for protecting ischemic myocardial cells when a fibrinolytic agents was employed in 
order to restore coronary blood flow needs further investigation. Infarct sizes from groups A, B, 
and C were analyzed according to whether thrombolysis occurred, and if so did reocclusion occur, 
the smallest infarct size was found in the group with initial thrombolysis and persistently patent 
vessels (16.9 f 3.7%, n=7, Figure 4) and this was significantly smaller than the infarct sizes when 
thrombolysis never occurred Q~0.02). In the computation of infarct sizes according to patency the 
dog where the infusion was started late was included. 
for Group CL In the two dogs that received 3.2 mg/kg total dose of rscu-PA, extensive 
bleeding occurred necessitating significant crystalloid replacement to maintain hemodynamic 
stability. Changes in the measured coagulation parameters were profound 30 min after initiation of 
treatment: PT (>60 + 0 set), PlT (>150 f 0 set), fibrinogen (~15 + 0 mg/dl) and FSP (4608.0 f 
3584.0 pg/ml). The PT and P’lT are dependent upon fibrinogen from the plasma sample, and 
when it is depleted (I 15mg/dl) as in these studies, all three tests will be abnormal. The increased 
FSP suggest that the low fibrinogen was induced by systemic fibrinogenolysis. By the -end of the 
experiments, the values showed a tendency towards normalization: PT 36.5k23.5 set, PTT 
84.4k65.7 set, fibrinogen 15.5kO.5 mg/dl, FSP 4096kO pg/ml. Systemic fibrinogenolysis 
resulted in a time to induce repel-fusion which was short (12.6*3 mm), infarct size which was 
small (12.9 f 4%) and thrombus mass which was small (1.3 + 1.3 mg). Since group C was small 
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Eipure 4: Myocardial infarct size grouped according to the incidence of thrombolysis with 
persistently patent vessels, thrombolysis with reocclusion, and thrombosis due to failure of 
thrombolytic therapy. ( ** = ~~0.02) 
(n=2), any conclusions based on these data must be considered cautiously. 
Clinically, effective thrombolytic therapy used early (<4h after onset of symptoms) in acute 
myocardial infarction has been shown to improve myocardial function and patient survival (l-4). 
Streptokinase was the first thrombolytic agent used and it is the only agent where data exist to 
support the hypothesis that long-term mortality is reduced (3). Because of several problems with 
streptokinase, i.e. bleeding, antigenicity and rethrombosis, there is now a wide-spread interest in 
the second-generation thrombolytic agents which are more clot specific. Recombinant human 
tissue-type plasminogen activator (rt-PA) has been used for coronary thrombolysis in acute 
myocardial infarction and the results from several multicenter studies are available (4,28-30). 
Effective thrombolysis in humans according to those studies is accompanied by systemic 
fibrinolysis. In an animal study carried out in this laboratory, 1 mg/kg bolus tPA +l mgkg tPA 
infused over 3 hours (5.5 pg/kg/min) was an effective coronary thrombolytic agent in 78% of 
cases (7/9 dogs) and systemic fibrinolysis also was noted (18). 
Systemic fibrinolysis was not detected in previously reported preliminary experiments with 
scu-PA. However, there are now data available suggesting, that in humans the dose necessary to 
induce coronary artery thrombolysis also causes systemic fibrinogenolysis (20,21). Again, the 
dose found to be effective (31), was similar to the dose that was effective in the study reported 
herein. Systemic fibrinogenolysis was detected in our study and there may be several reasons for 
this: (1) effective doses are high enough to exceed the relative threshold of specificity of WI-PA 
and (2) inactivation of plasmin by alpha-2 antiplasmin was exceeded by the excessive formation of 
plasmin in the model. 
One of the striking results of this study is the finding that the same total dose administered in 
different regimens does produce remarkably different efficacy. Based on a one compartment 
model in dogs and an estimated t1/2 of 7.5 min for rscu-PA both regimens (group A and B) reach 
plasma concentrations of more than 100 nM. According to a report from Collen et al (32) in vitro 
lysis of a human plasma clot was achieved within lh when scu-PA was present at a concentration 
of 32 nM. Neglecting the interspecies differences one would assume that thombolysis should occur 
in both groups A and B described in this study. Based upon the results of this study one might 
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conclude the following: (a) there is a dose dependency of the velocity of the activation of 
plasminogen by rscu-PA and (b) the sigmoid dose response that was found by Collen et al (32) 
may be valid for actual plasma concentrations in an in vivo system. It is possible that the fibrin 
present in the thoracic wound in this model binds part of the administered fibrinolytic agent which 
results in a higher total dose needed to lyse the coronary artery thrombus. 
At this point it is important to discuss the differences between the canine model used in this study 
and other studies. Collen et al (11,12) describe effective thrombolysis being achieved without 
systemic fibrinogenolysis at a dose that was approximately three times smaller than the dose used 
in our study (0.3mg/kg vs lmglkg, respectively). Thrombosis induced with an intracoronary 
copper coil in the model used by the Leuven group and thrombosis induced via electrical 
stimulation of the coronary artery intima as in this study generate different types of thrombi with 
respect to the composition of the clot. Romson et al. studied the electrically induced thrombus and 
found that it resembles the platelet-rich thrombi found in postmortem studies of humans with 
coronary artery disease (22). Differences between the experimental models may account for the 
different findings with rt-PA . Lysis in our canine model was accompanied by systemic 
fibrinogenolysis (18) and the dose needed for thrombolysis was approximately three times higher 
than that used by the Leuven group (17). In a recent study, histology of the thrombi revealed the 
crucial role of the platelets as well as the changing composition of the thrombi over a short period 
of time which led to significant reduction of effective thrombolysis with urokinase (33). It is of 
interest that the doses necessary to induce thrombolysis in our model are similar to those proven to 
be effective in humans for both rt-PA and rscu-PA and that systemic fibrinolysis is present with 
both recombinant agents. Although the drugs were not studied simultaneously, it can be suggested 
that r&PA and rscu-PA are both effective in this model of coronary artery thrombosis/thrombolysis 
and that thrombolysis is usually achieved in the presence of systemic fibrinolysis. In these studies, 
the laboratory evideince of systemic fibrinolysis did not correlate with overt bleeding in the 
open-chest model and severe blood loss only occurred at a total dose three times higher than 
necessary to achieve effective reperfusion with rscu-PA. 
The mechanism of reocclusion after thrombolytic therapy is not fully understood. It is conceivable 
that platelets play a role in this phenomenon. In the protocol employed in this study, coronary 
blood flow is monitored continuously, thus the pattern of coronary blood flow leading to 
reocclusion can be observed, Oscillations in coronary blood flow have preceded reocclusion in 
studies using this model with other thrombolytic agents (18,26). The observed oscillations are 
similar to those seen when a circumferential coronary artery stenosis is present and occlusion 
occurs, and these oscillations can be abolished with ketanserin (34). With electrially induced 
thrombosis, prolonged vessel patency after streptokinase improved with prostacyclin and heparin 
(39, and initial thrombosis could be prevented with ibuprofen (23) or thromboxane synthetase 
inhibition (36). Stmptokinase and t-PA have been reported to cause hyperaggregation of platelets 
in rabbits (37). Although platelet activation has not been studied in dogs in this model, it could be 
contributing to the oscillations or cyclic flow variations in coronary blood flow which precede 
reocclusion. These fmdings indicate that the mechanisms of thrombosis and thrombolyis involve a 
complex interaction involving the vascular endothelium, circulating cellular elements and plasma 
clotting factors and their inhibitors. To our knowledge rscu-PA has not been reported to cause 
platelet hyperaggregability. The presence of platelets in a thrombus has, in fact, been reported to 
augment rscu-PA induced lysis (38). Since in this study there was a low rate of reocclusion and 
the flow pattern preceding reocclusion was different from studies with streptokinase and t-PA, it 
will be important to investigate the rheological and platelet activating properties of rscu-PA and 
other proposed tbrombolytic agents. 
Conclusions Recombinant single-chain urokinase plasminogen activator is an effective 
thrombolytic agent in this model of coronary thrombosis at doses comparable to those necessary 
for thrombolysis in humans. The high initial bolus (l/4 of the total dose) is impressive in its ability 
to promote early thrombolysis. When a small initial bolus is used with a similar total dose, It IS 
not effective. Further investigation is needed to resolve the following questions: 1) Should a 
loading dose which is 25% of the total dose be used as the clinical therapeutic regimen? (2) Should 
different methods of measuring coagulation factors be developed in order to distinguish between 
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lytic states that endanger patients and those that merely indicate effective thrombolysis? 
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